Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Finished Goods: 2017-2025

Historic Finished Goods for Adma Biologics (ADMA) over the last 8 years, with Sep 2025 value amounting to $64.3 million.

  • Adma Biologics' Finished Goods rose 2.02% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 2.02%. This contributed to the annual value of $48.1 million for FY2024, which is 31.54% down from last year.
  • As of Q3 2025, Adma Biologics' Finished Goods stood at $64.3 million, which was up 34.29% from $47.9 million recorded in Q2 2025.
  • Adma Biologics' 5-year Finished Goods high stood at $70.3 million for Q4 2023, and its period low was $17.5 million during Q2 2021.
  • For the 3-year period, Adma Biologics' Finished Goods averaged around $57.3 million, with its median value being $55.0 million (2023).
  • Its Finished Goods has fluctuated over the past 5 years, first surged by 257.16% in 2022, then slumped by 32.47% in 2025.
  • Over the past 5 years, Adma Biologics' Finished Goods (Quarterly) stood at $29.0 million in 2021, then skyrocketed by 101.60% to $58.5 million in 2022, then rose by 20.22% to $70.3 million in 2023, then tumbled by 31.54% to $48.1 million in 2024, then increased by 2.02% to $64.3 million in 2025.
  • Its Finished Goods was $64.3 million in Q3 2025, compared to $47.9 million in Q2 2025 and $46.6 million in Q1 2025.